Saturday 17 October 2026
Export CRSP’s income statement to Excel — free account
CRISPR Therapeutics AG
CRSP Healthcare Biotechnology
CRISPR Therapeutics AG’s revenue for fiscal 2025 (year ended December 2025) was $3.5 million, down 90.6% from fiscal 2024. In the quarter to June 2026, revenue grew 1,041.4%, EPS grew 60.8% and free cash flow grew 26.2%, each against the same quarter a year earlier.
49.30
2.22
−4.31%
Follow CRSP
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
393.06 | 1,113.61 | 1,343.49 | 154.35 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(63.04) | (41.96) | (50.95) | (69.92) | |
P/B ratio |
3.01 | 2.52 | 2.45 | 3.09 | |
Price to Tangible BV |
3.01 | 2.52 | 2.45 | 3.09 | |
EV/Sales |
260.28 | 661.18 | 845.25 | 110.31 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(9.43) | (6.78) | (8.60) | (13.98) | |
EV/FCF |
(9.39) | (6.76) | (8.58) | (13.95) | |
Quick Ratio |
17.79 | 17.92 | 13.25 | 16.10 | |
Current Ratio |
17.85 | 17.96 | 13.32 | 16.22 | |
Net Debt/EBITDA |
15.74 | 14.74 | 13.25 | 15.01 | |
Debt/Assets |
22.11% | 21.48% | 0.00% | 0.00% | |
Debt/Equity |
0.34 | 0.32 | 0.00 | 0.00 | |
Asset Turnover |
0.01 | 0.00 | 0.00 | 0.02 | |
Operating CF/Net income |
0.92 | 0.89 | 0.71 | 0.80 | |
Capex/Depreciation |
(0.15) | (0.12) | (0.09) | (0.02) | |
Research and Development Expense of Revenue |
683.87% | 4,703.29% | 9,667.36% | 6,625.65% | |
Selling, General and Administrative Expense of Revenue |
172.41% | 1,178.53% | 2,129.51% | 1,904.50% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
170.08% | 1,119.62% | 2,092.13% | 1,867.72% | |
Graham Net Nets |
0.28 | 0.34 | 0.35 | 0.27 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(8.73%) | (13.08%) | (12.43%) | (8.63%) | |
Free Cash Flow Yield |
(7.05%) | (8.78%) | (7.34%) | (5.12%) | |
Revenue per Share |
0.11 | 0.02 | 0.01 | 0.01 | |
Operating CF per Share |
(0.87) | (1.13) | (1.03) | (0.93) | |
Capex per Share |
(0.01) | (0.01) | (0.01) | 0.00 | |
Free Cash Flow per Share |
(0.87) | (1.14) | (1.03) | (0.93) | |
Cash per Share |
24.50 | 25.42 | 21.97 | 20.98 | |
Shareholders Equity per Share |
18.10 | 18.89 | 21.37 | 20.98 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
18.10 | 18.89 | 21.37 | 20.98 | |
Free Cash Flow |
(84.15) | (109.40) | (93.07) | (84.71) | |
Working Capital |
2,238.87 | 2,312.08 | 1,836.55 | 1,810.14 | |
Capital Expenditures |
(0.65) | (0.50) | (0.52) | (0.07) | |
Net Current Asset Value |
1,467.55 | 1,537.10 | 1,642.24 | 1,599.77 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.06 | 0.35 | 0.60 | 0.08 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Payables |
10.53 | 13.36 | 12.92 | 13.69 | |
Average Assets |
2,340.24 | 2,445.96 | 2,253.64 | 2,250.72 | |
Average Common Equity |
1,728.84 | 1,821.86 | 1,926.95 | 1,927.82 |
Columns are period end dates